Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancerChristian J. Maine, Sadaf Ghaem‐Maghami, Nor Haslinda Abd Aziz et al.|Cancer Immunology Immunotherapy|2013Cited by 126
Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Clinical Cancer Research|2016Cited by 51
Supplementary Figure S1 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0
Supplementary Figure S4 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0
Supplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0